Crohn's disease: future anti-tumor necrosis factor therapies beyond infliximab

被引：10
|
作者：
Korzenik, JR [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Internal Med, Gastrointestinal Unit, Boston, MA 02114 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2004年 / 33卷 / 02期
关键词：
D O I：
10.1016/j.gtc.2004.02.009
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
The dramatic benefit experienced by many Crohn's patients treated with the anti-tumor necrosis factor-alpha (TNF-alpha) antibody infliximab underscores the centrality of this cytokine in the pathogenesis of Crohn's disease and the potential use of the therapeutic strategy of blocking TNF-alpha in this disease. In the hopes of emulating and improving on the success of infliximab, numerous strategies are being devised and studied to inhibit the actions of TNF-alpha. This article focuses on those agents, other than infliximab, which target TNF-alpha to treat inflammatory bowel disease as their central mechanism of action.
引用
收藏
页码：285 / +
页数：18
相关论文
共 50 条
  • [31] Rash induced by anti-tumor necrosis factor agents in an adolescent with Crohn's disease
    Conklin, Laurie S.
    Cohen, Bernard
    Wilson, Lindsay
    Cuffari, Carmen
    Oliva-Hemker, Maria
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2010, 7 (03) : 174 - 177
  • [32] Use of Vitamin D With Anti-Tumor Necrosis Factor Therapy for Crohn's Disease
    Bafutto, Mauro
    Oliveira, Enio Chaves
    Rezende Filho, Joffre
    GASTROENTEROLOGY RESEARCH, 2020, 13 (03) : 101 - 106
  • [33] Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
    Kim, Eun Sil
    Kang, Ben
    WORLD JOURNAL OF GASTROENTEROLOGY, 2023, 29 (18) : 2784 - 2797
  • [34] Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
    Vermeire, S
    Louis, E
    Carbonez, A
    Van Assche, G
    Noman, M
    Belaiche, J
    De Vos, M
    Van Gossum, A
    Pescatore, P
    Fiasse, R
    Pelckmans, P
    Reynaert, H
    D'Haens, G
    Rutgeerts, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (09): : 2357 - 2363
  • [35] Infliximab vs adalimumab:Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn's disease
    Eun Sil Kim
    Ben Kang
    World Journal of Gastroenterology, 2023, (18) : 2784 - 2797
  • [36] The Use of Anti-Tumor Necrosis Factor Agents and Development of Psoriasis in Patients with Crohn's Disease
    Lin, Ming
    Blonski, Wojciech
    Weiner, Mark
    Tierney, Ann
    Marchioni, Renee
    Buchner, Anna
    Lichtenstein, Gary
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S490 - S491
  • [37] Psoriasis during anti-tumor necrosis factor-alpha therapy for Crohn's disease
    Umeno, Junji
    Matsumoto, Takayuki
    Jo, Yukihiko
    Ichikawa, Miki
    Urabe, Kazunori
    Lida, Mitsuo
    INFLAMMATORY BOWEL DISEASES, 2007, 13 (09) : 1188 - 1189
  • [38] Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease
    Esters, N
    Vermeire, S
    Joossens, S
    Noman, M
    Louis, E
    Belaiche, J
    De Vos, M
    Van Gossum, A
    Pescatore, P
    Fiasse, R
    Pelckmans, P
    Reynaert, H
    Poulain, D
    Bossuyt, X
    Rutgeerts, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (06): : 1458 - 1462
  • [39] Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease
    Netz, Uri
    Carter, Jane Victoria
    Eichenberger, Maurice Robert
    Dryden, Gerald Wayne
    Pan, Jianmin
    Rai, Shesh Nath
    Galandiuk, Susan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (27) : 4958 - 4967
  • [40] Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease
    Uri Netz
    Jane Victoria Carter
    Maurice Robert Eichenberger
    Gerald Wayne Dryden
    Jianmin Pan
    Shesh Nath Rai
    Susan Galandiuk
    World Journal of Gastroenterology, 2017, 23 (27) : 4958 - 4967
12345